[1]梁源,孙立君,尹悦,等.消化内分泌与糖脂代谢[J].国际内分泌代谢杂志,2021,41(04):290-294.[doi:10.3760/cma.j.cn121383-20210415-05028]
　Liang Yuan,Sun Lijun,Yin Yue,et al.Gut endocrine in glucose and lipid metabolism[J].International Journal of Endocrinology and Metabolism,2021,41(04):290-294.[doi:10.3760/cma.j.cn121383-20210415-05028]
点击复制

消化内分泌与糖脂代谢()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年04期
页码:
290-294
栏目:
肠道内分泌与代谢性疾病专题
出版日期:
2021-07-20

文章信息/Info

Title:
Gut endocrine in glucose and lipid metabolism
作者:
梁源; 孙立君; 尹悦; 张炜真
北京大学医学部生理学与病理生理学系 100191
Author(s):
Liang Yuan;  Sun Lijun;  Yin Yue;  Zhang Weizhen.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing 100191, China
关键词:
胃肠道内分泌细胞;  胃肠道激素;  糖脂代谢;  2型糖尿病;  肥胖
Keywords:
Gastrointestinal endocrine cells;  Gastrointestinal hormones;  Glucolipid metabolism;  Type 2 diabetes mellitus;  Obesity
DOI:
10.3760/cma.j.cn121383-20210415-05028
摘要:
消化道内分泌细胞及其分泌的多种激素通过外周和中枢等多种作用途径参与调节机体糖脂代谢。研究发现,胃饥饿素(ghrelin)、促胰液素(secretin)、胆囊收缩素(CCK)、胰高血糖素样肽-1(GLP-1)、肠抑胃肽(GIP)和多肽YY(PYY)等胃肠激素控制食物的摄入、消化与吸收,调节胰岛素分泌,并作用于肝脏、脂肪等外周代谢器官调节机体糖脂稳态。肥胖、2型糖尿病等代谢性疾病与胃肠激素分泌异常密切相关。因此,以胃肠激素作为干预靶点的药物备受关注。对消化道内分泌细胞与激素的深入研究将为治疗代谢性疾病提供新方向。
Abstract:
Gastrointestinal endocrine cells and relevant hormones function to regulate glucose and lipid metabolism through both peripheral and central pathways. Studies have showed that gastrointestinal hormones including ghrelin, secretin, cholecystokinin(CCK), glucagon-like peptide-1(GLP-1), gastric inhibitory peptide(GIP)and peptideYY(PYY), play pivotal roles in the modulation of food intake, insulin secretion and lipid metabolism in peripheral organs. Metabolic diseases such as obesity and type 2 diabetes are closely related to gastrointestinal hormone abnormalities. Further study of gastrointestinal endocrine cells and hormones will provide a novel strategy for the treatment of metabolic diseases.

参考文献/References:

[1] Li Z,Yu R,Yin W,et al.mTOR signaling in X/A-like cells contributes to lipid homeostasis in mice[J].Hepatology,2019,69(2):860-875.DOI:10.1002/hep.30229.
[2] Xu G,Li Y,An W,et al.Gastric mammalian target of rapamycin signaling regulates ghrelin production and food intake[J].Endocrinology,2009,150(8):3637-3644.DOI:10.1210/en.2009-0372.
[3] Asakawa A,Inui A,Kaga T,et al.Antagonism of ghrelin receptor reduces food intake and body weight gain in mice[J].Gut,2003,52(7):947-952.DOI:10.1136/gut.52.7.947.
[4] Yu R,Li Z,Liu S,et al.Activation of mTORC1 signaling in gastric X/A-like cells induces spontaneous pancreatic fibrosis and derangement of glucose metabolism by reducing ghrelin production[J].EBioMedicine,2018,36:304-315.DOI:10.1016/j.ebiom.2018.09.027.
[5] Li Z,Xu G,Qin Y,et al.Ghrelin promotes hepatic lipogenesis by activation of mTOR-PPARγ signaling pathway[J].Proc Natl Acad Sci U S A,2014,111(36):13163-13168.DOI:10.1073/pnas.1411571111.
[6] Steinert RE,Feinle-Bisset C,Asarian L,et al.ghrelin,CCK,GLP-1,and PYY(3-36):secretory controls and physiological roles in eating and glycemia in health,obesity,and after RYGB[J].Physiol Rev,2017,97(1):411-463.DOI:10.1152/physrev.00031.2014.
[7] Otto B,Cuntz U,Fruehauf E,et al.Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa[J].Eur J Endocrinol,2001,145(5):669-673.
[8] Zheng F,Yin X,Lu W,et al.Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in type 2 diabetic patients[J].J Endocrinol Invest,2013,36(7):489-496.DOI:10.3275/8811.
[9] Li Y,Schnabl K,Gabler SM,et al.Secretin-activated brown fat mediates prandial thermogenesis to induce satiation[J].Cell,2018,175(6):1561-1574.DOI:10.1016/j.cell.2018.10.016.
[10] Okonkwo O,Zezoff D,Adeyinka A.Biochemistry,Cholecystokinin[J/OL].Treasure Island(FL):StatPearls Publishing; 2021 [2021-05-09].https://www.ncbi.nlm.nih.gov/books/NBK534204/.
[11] Kreymann B,Ghatei MA,Williams G,et al.Glucagon-like peptide-17-36:a physiological incretin in man[J].Lancet,1987,2:1300-1304.DOI:10.1016/s0140-6736(87)91194-9.
[12] Baggio LL,Drucker DJ.Biology of incretins:GLP-1 and GIP[J].Gastroenterology,2007,132(6):2131-2157.DOI:10.1053/j.gastro.2007.03.054.
[13] Xu G,Kaneto H,Laybutt DR,et al.Downregulation of GLP-1 and GIP receptor expression by hyperglycemia:possible contribution to impaired incretin effects in diabetes[J].Diabetes,2007,56(6):1551-1558.DOI:10.2337/db06-1033.
[14] Xu G,Li Z,Ding L,et al.Intestinal mTOR regulates GLP-1 production in mouse L cells[J].Diabetologia,2015,58(8):1887-1897.DOI:10.1007/s00125-015-3632-6.
[15] Oduori OS,Murao N,Shimomura K,et al.Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes[J].J Clin Invest,2020,130(12):6639-6655.DOI:10.1172/JCI140046.
[16] Miyawaki K,Yamada Y,Ban N,et al.Inhibition of gastric inhibitory polypeptide signaling prevents obesity[J].Nat Med,2002,8(7):738-742.DOI:10.1038/nm727.
[17] Speliotes EK,Willer CJ,Berndt SI,et al.Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index[J].Nat Genet,2010,42(11):937-948.DOI:10.1038/ng.686.
[18] Irwin N,Flatt PR.Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications[J].Diabetologia,2009,52(9):1724-1731.DOI:10.1007/s00125-009-1422-8.
[19] McGowan BM,Bloom SR.Peptide YY and appetite control[J].Curr Opin Pharmacol,2004,4(6):583-588.DOI:10.1016/j.coph.2004.06.007.
[20] Boey D,Heilbronn L,Sainsbury A,et al.Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes[J].Neuropeptides,2006,40(5):317-324.DOI:10.1016/j.npep.2006.08.002.
[21] Pi-Sunyer X,Astrup A,Fujioka K,et al.A randomized,controlled trial of 3.0 mg of liraglutide in weight management[J].N Engl J Med,2015,373(1):11-22.DOI:10.1056/NEJMoa1411892.
[22] Frias JP,Nauck MA,Van J,et al.Efficacy and safety of LY3298176,a novel dual GIP and GLP-1 receptor agonist,in patients with type 2 diabetes:a randomised,placebo-controlled and active comparator-controlled phase 2 trial[J].Lancet,2018,392(10160):2180-2193.DOI:10.1016/S0140-6736(18)32260-8.
[23] Will S,Hornigold DC,Baker DJ,et al.Gut check on diabesity:leveraging gut mechanisms for the treatment of type 2 diabetes and obesity[J].Curr Opin Pharmacol,2017,37:10-15.DOI:10.1016/j.coph.2017.07.010.
[24] Liang Y,Yin W,Yin Y,et al.ghrelin based therapy of metabolic diseases[J].Curr Med Chem,2021,28(13):2565-2576..DOI:10.2174/0929867327666200615152804.

相似文献/References:

[1]刘剑 吴明昊 高宇.高脂饮食影响消化系统致肥胖的机制[J].国际内分泌代谢杂志,2015,(06):402.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.011]
　Liu Jian*,Wu Minghao,Gao Yu..The mechanism of obesity caused by disturbance of high fat diets on gastrointestinal system[J].International Journal of Endocrinology and Metabolism,2015,(04):402.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.011]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81730020,81930015,82070592); 科技部资助课题(2017YFC0908900)
通信作者:尹悦,Emai: Yueyin@hsc.pku.edu.cn; 张炜真,Email:weizhenzhang@bjmu.edu.cn
更新日期/Last Update: 1900-01-01